<DOC>
	<DOCNO>NCT01133613</DOCNO>
	<brief_summary>The objective study determine safety tolerability two different formulation BMP-7 treatment osteoarthritis knee .</brief_summary>
	<brief_title>Double-Blind , Randomized , Single Dose Escalation Safety Study Intraarticular Bone Morphogenic Protein ( 38A BMP-7 ) Subjects With Osteoarthritis ( OA ) Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Inclusion Criteria Ambulatory diagnosis OA knee symptom least 6 month pain majority day last 30 day . &gt; 40 year Radiographic evidence least one osteophyte either knee screening Exclusion Criteria Concurrent medical arthritis condition could interfere evaluation index knee joint ( include fibromyalgia ) Unwilling abstain NSAIDs and/or analgesic medication 48 hr prior assessment . Subjects remain acetaminophen 3.0 g daily . Received arthroscopic open surgery index knee within 6 month screen History joint replacement surgery ( index knee ) . Corticosteroid , short act hyaluronic acid , intraarticular injection index knee within 3 month screen Long act hyaluronic acid injection index knee within 6 month screen History Reiter 's syndrome , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis , lymphoma , arthritis associate inflammatory bowel disease , sarcoidosis , amyloidosis fibromyalgia . History malignancy exception resect basal cell , squamous cell skin , resect cervical atypia carcinoma situ . Female subject reproductive capability .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>